GenMont Biotech Incorporation (3164.TW)
TWD 19.95
(-1.24%)
TWD 19.95
(-1.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 204.05 Million TWD | 2.75% |
| 2022 | 198.59 Million TWD | 14.36% |
| 2021 | 173.64 Million TWD | 32.61% |
| 2020 | 130.95 Million TWD | 6.43% |
| 2019 | 123.04 Million TWD | 28.7% |
| 2018 | 95.6 Million TWD | -26.13% |
| 2017 | 129.41 Million TWD | 4.25% |
| 2016 | 124.14 Million TWD | -6.96% |
| 2015 | 133.43 Million TWD | -7.82% |
| 2014 | 144.75 Million TWD | -73.02% |
| 2013 | 536.48 Million TWD | -4.74% |
| 2012 | 563.16 Million TWD | -3.77% |
| 2011 | 585.25 Million TWD | -6.76% |
| 2010 | 627.65 Million TWD | 609.88% |
| 2009 | 88.41 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 269.92 Million TWD | 32.28% |
| 2024 Q2 | 250.31 Million TWD | -7.26% |
| 2023 Q4 | 204.05 Million TWD | 18.41% |
| 2023 FY | 204.05 Million TWD | 2.75% |
| 2023 Q2 | 215.05 Million TWD | -13.26% |
| 2023 Q3 | 172.33 Million TWD | -19.87% |
| 2023 Q1 | 247.92 Million TWD | 24.84% |
| 2022 Q1 | 157.8 Million TWD | -9.13% |
| 2022 Q2 | 210.87 Million TWD | 33.63% |
| 2022 FY | 198.59 Million TWD | 14.36% |
| 2022 Q4 | 198.59 Million TWD | 19.55% |
| 2022 Q3 | 166.1 Million TWD | -21.23% |
| 2021 FY | 173.64 Million TWD | 32.61% |
| 2021 Q1 | 141.33 Million TWD | 7.93% |
| 2021 Q2 | 145.32 Million TWD | 2.82% |
| 2021 Q3 | 131.31 Million TWD | -9.64% |
| 2021 Q4 | 173.64 Million TWD | 32.24% |
| 2020 Q2 | 176.47 Million TWD | 37.18% |
| 2020 Q3 | 121.8 Million TWD | -30.98% |
| 2020 Q4 | 130.95 Million TWD | 7.51% |
| 2020 Q1 | 128.64 Million TWD | 4.55% |
| 2020 FY | 130.95 Million TWD | 6.43% |
| 2019 Q1 | 129.55 Million TWD | 35.51% |
| 2019 Q3 | 119.13 Million TWD | -51.85% |
| 2019 Q4 | 123.04 Million TWD | 3.28% |
| 2019 FY | 123.04 Million TWD | 28.7% |
| 2019 Q2 | 247.42 Million TWD | 90.98% |
| 2018 Q2 | 125.4 Million TWD | -12.56% |
| 2018 Q4 | 95.6 Million TWD | 0.37% |
| 2018 FY | 95.6 Million TWD | -26.13% |
| 2018 Q1 | 143.41 Million TWD | 10.82% |
| 2018 Q3 | 95.25 Million TWD | -24.04% |
| 2017 Q2 | 111.29 Million TWD | -3.08% |
| 2017 FY | 129.41 Million TWD | 4.25% |
| 2017 Q4 | 129.41 Million TWD | 0.05% |
| 2017 Q3 | 129.34 Million TWD | 16.22% |
| 2017 Q1 | 114.82 Million TWD | -7.5% |
| 2016 Q1 | 119.35 Million TWD | -10.55% |
| 2016 Q2 | 117.59 Million TWD | -1.48% |
| 2016 Q3 | 130.09 Million TWD | 10.63% |
| 2016 Q4 | 124.14 Million TWD | -4.57% |
| 2016 FY | 124.14 Million TWD | -6.96% |
| 2015 Q1 | 128.48 Million TWD | -11.24% |
| 2015 Q3 | 143.36 Million TWD | 15.44% |
| 2015 Q2 | 124.18 Million TWD | -3.34% |
| 2015 FY | 133.43 Million TWD | -7.82% |
| 2015 Q4 | 133.43 Million TWD | -6.93% |
| 2014 Q4 | 144.75 Million TWD | -89.33% |
| 2014 FY | 144.75 Million TWD | -73.02% |
| 2014 Q2 | 1.35 Billion TWD | -14.79% |
| 2014 Q3 | 1.35 Billion TWD | 0.07% |
| 2014 Q1 | 1.59 Billion TWD | 196.56% |
| 2013 Q2 | 529.39 Million TWD | -29.53% |
| 2013 Q3 | 505.7 Million TWD | -4.48% |
| 2013 Q4 | 536.48 Million TWD | 6.09% |
| 2013 FY | 536.48 Million TWD | -4.74% |
| 2013 Q1 | 751.24 Million TWD | 33.4% |
| 2012 Q4 | 563.16 Million TWD | -2.74% |
| 2012 Q3 | 579.06 Million TWD | -7.25% |
| 2012 Q2 | 624.34 Million TWD | 7.75% |
| 2012 Q1 | 579.41 Million TWD | -1.0% |
| 2012 FY | 563.16 Million TWD | -3.77% |
| 2011 Q1 | 581.19 Million TWD | -7.4% |
| 2011 Q2 | 726.4 Million TWD | 24.98% |
| 2011 Q3 | 601.33 Million TWD | -17.22% |
| 2011 Q4 | 585.25 Million TWD | -2.67% |
| 2011 FY | 585.25 Million TWD | -6.76% |
| 2010 FY | 627.65 Million TWD | 609.88% |
| 2010 Q4 | 627.65 Million TWD | 0.0% |
| 2009 FY | 88.41 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Apex Biotechnology Corp. | 500.07 Million TWD | 59.194% |
| Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 92.848% |
| Panion & Bf Biotech Inc. | 1.32 Billion TWD | 84.589% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | 88.797% |
| Abnova (Taiwan) Corporation | 69.42 Million TWD | -193.931% |
| Adimmune Corporation | 3.7 Billion TWD | 94.495% |
| Tanvex BioPharma, Inc. | 1.94 Billion TWD | 89.494% |
| Polaris Group | 1.46 Billion TWD | 86.069% |
| Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -729.947% |
| UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -128.032% |
| PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | 13.814% |